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Abstract  Lipoprotein(a)  (Lp(a))  was  first  described  by 
K.  Berg  and  is  known  for  more  than  50  years.  It  is  an 
interesting particle  and  combines  the  atherogenic  proper-
ties  of  low-density  lipoprotein  (LDL)-cholesterol  as well 
as  the  thrombogenic  properties  of  plasminogen  inactiva-
tion. However, due to  technical problems and publication 
of negative trials the potential role of Lp(a) in atheroscle-
rosis  was  severely  underestimated.  In  recent  years  our 
understanding  of  the  function  and  importance  of  Lp(a) 
improved.  Interventional  trials with niacin  failed  to dem-
onstrate  any  benefit  of  lowering  Lp(a);  however,  several 
studies  confirmed  the  residual  cardiovascular  disease 
(CVD) risk of elevated Lp(a). LDL/Lp(a) apheresis is able 
to  lower  Lp(a)  and  some  new  drugs  under  development 
should help us to lower Lp(a) in the near future. It will be 








Lipoprotein(a) – klinische Aspekte und zukünftige 
Herausforderungen
Zusammenfassung Lp(a)  wurde  erstmals  von  K.  Berg 









nis  bezüglich  der  Funktion  und Bedeutung  von Lp(a)  für 
die  Atherosklerose  deutlich  gebessert.  Medikamentenstu-
dien mit der Nikotinsäure zeigten trotz einer Senkung des 
Lp(a)  keinen  Nutzen,  dagegen  wurde  die  Bedeutung  von 
erhöhtem Lp(a) für die Atherosklerose in mehreren Studien 
bestätigt.  Die  LDL/Lp(a) Apherese  ist  in  der  Lage  Lp(a) 
deutlich zu senken. Zudem sind einige neuere Medikamen-
te in Entwicklung, die ebenfalls Lp(a) senken können. Hier 
wird  es wichtig  sein,  deren Effekte  auch  im Rahmen von 
Studien mit  harten  klinischen  Endpunkten  zu  überprüfen. 
Bis  dahin  werden  die  meisten  Ärzte  bei  Ihren  Patienten 
mit hohem Lp(a) eine intensivierte LDL senkende Therapie 
durchführen  sowie  additive  Risikofaktoren  entsprechend 
angehen. Da die meisten der Patienten mit hohem Lp(a) 
Spiegel ohnehin bereits eine manifeste Atherosklerose ha-
ben  dürften,  sollte  auch  über  den  Einsatz  von Acetylsali-
cylsäure nachgedacht werden.
Schlüsselwörter Lipoprotein(a) · Lp(a) · koronare 
Herzerkrankung · Prävention · lipidsenkende Therapie
































several  follow-up  publications  performing  meta-analysis 
of  long-term  prospective  studies  that  recorded  Lp(a)  and 
vascular morbidity  and/or mortality  by which  they  found 
only a modest association of Lp(a) concentration with risk 
of  coronary  heart  disease  (CHD)  and  stroke  [6]. Interest-
ingly enough, due to the ease of analysis, there were mostly 
genetic studies which reintroduced sight of and interest  in 
Lp(a) as an independent CVD risk factor [7]. Clarke et al. 








controls  followed  by  genotyping  of  top  association  sig-
nals  in  56,682  additional  individuals.  By  this  Schunkert 
et  al. were  able  to  identify  13  loci  newly  associated with 
CAD and confirmed the association of 10 of 12 previously 
reported CAD loci, including rs3798220 of Lp(a) [9].
Structure and function of Lp(a)
Lp(a)  is  basically  a  composite  structure  of  low-density 
lipoprotein (LDL) which binds by a disulfide bridge to an 
additional  glycoprotein,  the  so-called  apolipoprotein(a) 
(= apo(a)). Both together, the LDL and apo(a) form the Lp(a) 
particle  (Fig.  1)  [10].  The  apo(a)  protein  part  has  a  total 
of  five  cysteine-rich  domains which  are  called  “kringles” 
with  the  fourth kringle being homologous with plasmino-
gen [11]. Plasminogen  is a protein which—once activated 
by  tissue plasminogen activator  (tPA)  to plasmin—is able 
to  resolve  blood  clots.  Apo(a)  is  able  to  interfere  with 











measure Lp(a)  at  all. Some physicians deny  the measure-
ment not only  for  costs but  also  for  the  lack of  treatment 
options to lower Lp(a). Kostner et al. see that  the consen-
sus reports of scientific societies are currently still prudent 
in  recommending  the measurement  of Lp(a)  routinely  for 
assessing  CVD  risk.  For  example,  the  present  European 
consensus  statement  recommends  Lp(a)  measurement  in 
subjects with a 10-year risk of fatal CVD 3 % and more [14]. 
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kg/d)  as well  as  for  apoB-100  (1.31 nmol/kg/d)  both  iso-
lated  from Lp(a).  These were  significantly  different  from 
the PR  for apoB-100  isolated  from LDL, 32.6 nmol/kg/d. 
Also  mean  fractional  synthetic  rate  (FSR)  and  residence 
time (RT) values for Lp(a)–apo(a) were similar to those of 
Lp(a)–apoB and different from those for LDL–apoB. From 
these  studies we were able  to conclude  that  there are  two 
different  kinetic  apoB  pools within  Lp(a)  and  LDL. This 
again suggests  intracellular  (or close  to  the cellular mem-
brane) Lp(a) assembly from apo(a) and newly synthesized 





ing  in  vivo  turnover  studies  where  the  tracer  enrichment 
of apoB from Lp(a) was comparable to that of LDL apoB. 
This might be due to differences of the study protocol such 
as  fasting  versus  fed  status;  however  technical  problems 
such as minor LDL apoB contaminations might also have 





gel  electrophoresis  (SDS PAGE)  separation of  apo(a)  and 
apoB-100, respectively.
Lp(a) in renal disease
It  is  well  known  that  patients  with  chronic  renal  disease 




Kostner’s  observation we  performed  in  vivo  kinetic  stud-
ies  in  hemodialysis  patients  utilizing  stable  isotope  label-
ing  of  lipoproteins  including Lp(a)  (see  section  “Lp(a)  in 
vivo kinetics” above). By this we were able to confirm that 





















rent  or  rapidly  progressive  vascular  disease  despite  being 
on lipid-lowering medication; (2) familial hypercholesterol-
emia (FH) or other forms of genetic dyslipidemias; (3) low 
high-density  lipoprotein  cholesterol  (HDL-C);  (4)  genetic 
defects related to hemostasis and homocysteine; (5) diabe-
tes mellitus; (6) renal disease; and (7) autoimmune diseases.
Lp(a) in vivo kinetics







residence  times.  However  in  certain  disease  states,  such 
as  chronic  renal  failure,  Lp(a)  in  vivo metabolism differs 
from normal. By utilizing a stable isotope tracer technique 
(3Deuterium-labeled L-Leucine) we found normal produc-
tion rates of Lp(a) in patients with renal failure undergoing 
hemodialysis. However the Lp(a) residence time was twice 
as long as normal. This finding explains the elevated Lp(a) 





contamination with  apoB-100  from  the LDL particles. To 
answer this question, endogenous labeling of both proteins, 
the  apo(a)  as well  as  the  apoB part  of  the Lp(a)  particle, 
in  addition  to  apoB  from  very  low-density  lipoprotein 
(VLDL),  intermediate-density lipoprotein (IDL), and LDL 
is an appropriate approach. For this we performed in vivo 
turnover  studies  utilizing  3Deuterium-labeled  L-Leucine 
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nucleotides, apo(a) antisense oligonucleotides, microsomal 














P = 0.02)  and  the  on-statin-treatment  Lp(a)  concentrations 
demonstrated a residual risk of cardiovascular disease (HR 
1.27;  95 %  confidence  interval,  1.01–1.59; P = 0.04). This 










for  this Lp(a)-lowering effect  by monoclonal  antibody  to 
PCSK9  is  currently  unclear.  Studies  in  homozygote  FH 
patients with no LDL receptor (LDLR) expression showed 
an LDLR-unrelated decrease in Lp(a), indicating that Lp(a) 
catabolism  is  not  driven  primarily  by  the  LDLR. At  this 






Roubtsova et  al.  could  show  that VLDLR  is  regulated  in 
part  by  endogenous  PCSK9  as well. They  found  in  their 
found  a  significant  reduction  of  CAD  events  under  LDL 
apheresis compared to the time before this treatment [23]. 
In  addition most  recently  Leebmann  et  al.  performed  the 
Pro(a)LiFe study as a prospective observational multicenter 
trial  to  study  the  effect  of  chronic  lipoprotein  apheresis 
on  cardiovascular  events  in 170 patients undergoing LDL 
apheresis  to  lower Lp(a). They  found a clear  reduction of 
events in a timeframe of 2 years under treatment compared 




Treatment to lower Lp(a)
The  treatment  of  elevated  Lp(a)  is  troublesome  since we 
have no real good drug treatment available to lower elevated 
Lp(a) (Table 4). The only established Lp(a)-lowering treat-
ment  is  the  use  of  nicotinic  acid,  fibrates,  or  performing 
LDL/Lp(a) apheresis.  In addition  there are new classes of 
upcoming—or  currently  studied—therapeutic  agents  with 
some Lp(a)-lowering effect, such as apoB antisense oligo-













Liver diseases Up to 90 % reduction
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ing drugs. So far nicotinic acid (2–4 g/day) was considered 
the most effective  therapy  to  reduce Lp(a) by as much as 
38 %.  In  addition,  nicotinic  acid  lowers  LDL  cholesterol, 
apo B-100,  and  triglycerides,  and  raises HDL cholesterol. 
However, most recently  the so-called AIM-HIGH (athero-
thrombosis  intervention  in  metabolic  syndrome  with  low 
HDL/high  triglyceride  and  impact  on  global  health  out-
comes) trial ended without any clinical benefit. AIM-HIGH 
had a treatment arm randomized to simvastatin plus placebo 




in  both  simvastatin  plus  placebo  and  the  simvastatin  plus 
ERN group. However, despite the fact that ERN decreased 
Lp(a)  by 21 %  there was no  reduction of CV events. The 
authors conclude that (1) Lp(a) is associated with increased 
CV risk in both treatment groups indicating that it contrib-
utes  to residual CV risk; and (2)  there  is no evidence that 
ERN is able to reduce CV risk despite lowering Lp(a) [36]. 
This finding underlines that we need hard endpoint data to 






to  plasminogen  interaction,  it  might  be  wise  to  consider 
antithrombotic treatment approaches, especially in patients 
with high Lp(a). Chasman  et  al.  studied  the genotypes of 
rs3798220  in  25,131  initially  healthy  Caucasian  subjects 
of  the Women’s  Health  Study  [37].  Median  Lp(a)  levels 
at  baseline  were  10.0,  79.5,  and  153.9  mg/dL  for  major 
allele homozygotes, heterozygotes, and minor allele homo-
zygotes,  respectively  (P < 0.0001). Chasman et al. found 
during 9.9 years of follow-up that subjects with the minor 
allele (3.7 %) had a twofold higher risk of major cardiovas-
cular  events  than noncarriers  (HR = 2.21, 95 % confidence 
interval,  CI:  1.39–3.52).  Interestingly  the  treatment  with 
acetylsalicylic  acid  reduced  the  risk  more  than  twofold 







PCSK9(−/−)  mice  model  a  40-fold  higher  cell  surface 
level  of VLDLR and  an  accumulation of  80 % more vis-
ceral adipose tissue compared to wild mice. Roubtsova et 
al.  conclude  that  PCSK9  is  pivotal  in  fat metabolism  by 
maintaining  high  circulating  cholesterol  levels  due  to  an 
increase  of  hepatic  LDLR  degradation  and  limiting  vis-
ceral  adipogenesis  by  regulating  the  adipose  VLDLR 
[30].  Taking  these  studies  together  we  would  speculate 
that  the  decrease  of  Lp(a)  under  PCSK9  antibody  treat-
ment  can  be  explained  by  an  increased  binding  of  Lp(a) 
to  the  upregulated  VLDLR.  Our  hypothesis  would  also 
explain that Lp(a) can even be lowered by PCSK9 antibody 
treatment  in  homozygous  FH  patients.  Stein  et  al.  stud-
ied  eight  patients  with  LDLR-negative  (n = 2) or LDLR-
defective (n = 6) homozygous FH. They were treated with 
subcutaneous 420 mg evolocumab every 4 weeks for ≥ 12 
weeks,  followed  by  420  mg  evolocumab  every  2  weeks 
for an additional 12 weeks. In the six LDLR-defective FH 
























ment  with  mipomersen  and  found  a  reduction  of  plasma 
Lp(a) levels by 31 % [33]. Merki et al. studied whether an 
antisense oligonucleotide  (ASO) directed  to  apo(a) would 
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AIM-HIGH  trial  and  the use of  acetylsalicylic  acid needs 
to  be  proven  by  other  trials  as  well.  Clearly  the  current 
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